Synthesis and expression of functional angiotensin II receptors in Xenopus oocytes injected with rat brain mRNA. 1987

D Cross, and F Cifuentes, and J P Huidobro-Toro, and C P Vío, and N C Inestrosa
Department of Cell Biology, Catholic University of Chile, Santiago.

Xenopus laevis oocytes were injected with poly(A)+ mRNA isolated from rat brain and superfused in a medium containing either serotonin, angiotensin II or bradykinin. Applications of serotonin or angiotensin II to injected oocytes elicited, in a dose-dependent manner, changes in membrane potential. The angiotensin II receptor was desensitized fairly rapidly in the continued presence of the agonist. No response was obtained with bradykinin. The selectivity of the angiotensin II-induced response was demonstrated by the finding that the angiotensin II antagonist [( Sar1,Ala8]angiotensin II, saralasin) blocked the angiotensin II-induced response. It is concluded that an appropriate fraction of brain mRNA is capable of directing the synthesis and correct insertion of functional angiotensin II receptors in the Xenopus oocyte membrane.

UI MeSH Term Description Entries
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D008845 Microinjections The injection of very small amounts of fluid, often with the aid of a microscope and microsyringes. Microinjection
D009865 Oocytes Female germ cells derived from OOGONIA and termed OOCYTES when they enter MEIOSIS. The primary oocytes begin meiosis but are arrested at the diplotene state until OVULATION at PUBERTY to give rise to haploid secondary oocytes or ova (OVUM). Ovocytes,Oocyte,Ovocyte
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D011985 Receptors, Serotonin Cell-surface proteins that bind SEROTONIN and trigger intracellular changes which influence the behavior of cells. Several types of serotonin receptors have been recognized which differ in their pharmacology, molecular biology, and mode of action. 5-HT Receptor,5-HT Receptors,5-Hydroxytryptamine Receptor,5-Hydroxytryptamine Receptors,Receptors, Tryptamine,Serotonin Receptor,Serotonin Receptors,Tryptamine Receptor,Tryptamine Receptors,Receptors, 5-HT,Receptors, 5-Hydroxytryptamine,5 HT Receptor,5 HT Receptors,5 Hydroxytryptamine Receptor,5 Hydroxytryptamine Receptors,Receptor, 5-HT,Receptor, 5-Hydroxytryptamine,Receptor, Serotonin,Receptor, Tryptamine,Receptors, 5 HT,Receptors, 5 Hydroxytryptamine
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D005260 Female Females
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine

Related Publications

D Cross, and F Cifuentes, and J P Huidobro-Toro, and C P Vío, and N C Inestrosa
January 1984, Nature,
D Cross, and F Cifuentes, and J P Huidobro-Toro, and C P Vío, and N C Inestrosa
March 1994, Brain research. Molecular brain research,
D Cross, and F Cifuentes, and J P Huidobro-Toro, and C P Vío, and N C Inestrosa
December 1989, FEBS letters,
D Cross, and F Cifuentes, and J P Huidobro-Toro, and C P Vío, and N C Inestrosa
September 1990, Biochemical and biophysical research communications,
D Cross, and F Cifuentes, and J P Huidobro-Toro, and C P Vío, and N C Inestrosa
March 1990, FEBS letters,
D Cross, and F Cifuentes, and J P Huidobro-Toro, and C P Vío, and N C Inestrosa
November 1996, Journal of neurochemistry,
D Cross, and F Cifuentes, and J P Huidobro-Toro, and C P Vío, and N C Inestrosa
February 1991, Japanese journal of pharmacology,
D Cross, and F Cifuentes, and J P Huidobro-Toro, and C P Vío, and N C Inestrosa
January 2000, The International journal of neuroscience,
D Cross, and F Cifuentes, and J P Huidobro-Toro, and C P Vío, and N C Inestrosa
May 1988, Proceedings of the National Academy of Sciences of the United States of America,
D Cross, and F Cifuentes, and J P Huidobro-Toro, and C P Vío, and N C Inestrosa
July 1995, Brain research. Developmental brain research,
Copied contents to your clipboard!